Omada Health, Inc. (OMDA) Key Metrics
OMDA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.08B
- Enterprise value
- $1.07B
- P/E (TTM)
- 73.5
- Forward P/E
- 137.0
- PEG ratio
- —
- Price / sales
- 3.5
- Price / book
- 5.0
- EV / EBITDA
- 101.3
- Dividend yield
- —
- Beta
- —
OMDA key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOMDA returns How much profit the business earns on the capital it uses.
OMDA per-share figures Results divided by the shares outstanding at year-end.
OMDA financial health Debt, liquidity and how easily interest is covered.
OMDA efficiency & capital use Working capital cycle and where the cash goes.
OMDA valuation history
OMDA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OMDA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OMDA price vs earnings per share
OMDA key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $922.0M | — | — | — |
| Enterprise value | $700.0M | — | — | — |
| Price / sales | 3.5 | — | — | — |
| Price / book | 4.0 | — | — | — |
| Price / free cash flow | 54.5 | — | — | — |
| Price / operating cash flow | 50.5 | — | — | — |
| EV / sales | 2.7 | — | — | — |
| EV / free cash flow | 41.3 | — | — | — |
| Earnings yield | −1.4% | — | — | — |
| Free cash flow yield | 1.8% | — | — | — |
| Share price at fiscal year-end | $15.78 | — | — | — |
| Per share | ||||
| Revenue per share | $4.45 | $3.05 | $2.20 | $1.60 |
| Earnings per share | −$0.22 | −$0.85 | −$1.21 | −$1.30 |
| Operating cash flow per share | $0.31 | −$0.61 | −$0.89 | −$1.24 |
| Free cash flow per share | $0.29 | −$0.68 | −$0.94 | −$1.29 |
| Cash per share | $3.80 | $1.37 | $2.07 | $3.02 |
| Book value per share | $3.93 | $1.16 | $1.77 | $2.79 |
| Tangible book value per share | $3.66 | $0.85 | $1.42 | $2.40 |
| Capex per share | $0.02 | $0.07 | $0.05 | $0.05 |
| Debt per share | — | $0.54 | $0.55 | $0.55 |
| Shares outstanding | 58.4M | 55.7M | 55.7M | 55.7M |
| Change in shares outstanding | +4.8% | 0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −8.7% | −57.6% | −53.0% | −46.6% |
| Return on invested capital (ROIC) | −72.6% | −213.6% | −324.3% | −312.5% |
| Return on assets (ROA) | −5.6% | −28.9% | −34.0% | −32.7% |
| Return on tangible assets | −4.4% | −35.3% | −43.4% | −36.2% |
| Free cash flow margin | 6.5% | −22.4% | −42.9% | −80.4% |
| Financial health | ||||
| Total debt | — | $30.2M | $30.6M | $30.8M |
| Cash & short-term investments | $222.0M | $76.4M | $115.6M | $168.1M |
| Net debt | −$222.0M | −$46.2M | −$85.1M | −$137.3M |
| Debt / equity | — | 0.47 | 0.31 | 0.20 |
| Debt / assets | — | 0.20 | 0.17 | 0.14 |
| Current ratio | 3.60 | 2.10 | 3.26 | 5.46 |
| Quick ratio | 3.54 | 2.03 | 3.18 | 5.36 |
| Interest coverage | -4.7 | -9.7 | -14.0 | -17.2 |
| Working capital | $197.2M | $59.1M | $99.1M | $154.0M |
| Invested capital | $7.6M | $18.4M | $13.9M | $18.3M |
| Tangible asset value | $214.0M | $47.1M | $79.4M | $134.1M |
| Net current asset value | $197.2M | $26.8M | $66.7M | $122.4M |
| Graham net-net per share | $2.99 | $0.17 | $0.96 | $2.02 |
| Capital allocation | ||||
| Capex / revenue | 0.5% | 2.3% | 2.4% | 3.1% |
| Capex / operating cash flow | 7.2% | — | — | — |
| Capex / depreciation | 0.24 | 0.80 | 0.66 | 0.63 |
| Stock-based compensation / revenue | 5.0% | 5.5% | 7.1% | 7.5% |
| R&D / revenue | 15.6% | 21.2% | 27.5% | 29.3% |
| SG&A / revenue | 54.7% | 65.1% | 83.3% | 99.8% |
| Efficiency | ||||
| Days sales outstanding | 41.0 | 43.4 | 41.8 | 47.7 |
| Days of inventory on hand | 15.9 | 18.8 | 24.7 | 27.9 |
| Days payables outstanding | 29.5 | 21.2 | 26.7 | 32.3 |
| Cash conversion cycle (days) | 27.4 | 41.0 | 39.8 | 43.3 |
| Receivables turnover | 8.90 | 8.41 | 8.74 | 7.64 |
| Payables turnover | 12.36 | 17.18 | 13.67 | 11.30 |
| Inventory turnover | 22.94 | 19.37 | 14.76 | 13.11 |
| Asset turnover | 1.14 | 1.04 | 0.62 | 0.40 |
| Average receivables | $29.3M | $20.2M | $14.1M | $11.7M |
| Average payables | $7.2M | $3.9M | $3.9M | $4.1M |
| Average inventory | $3.9M | $3.5M | $3.6M | $3.5M |
| Intangibles / total assets | 5.1% | 11.6% | 11.1% | 9.7% |
Computed from OMDA's annual financial statements (latest annual report filed March 6, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OMDA valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 73.5 and the forward P/E is 137.0. Omada Health earned a return on equity of −8.7% and a return on invested capital of −72.6% in fiscal 2025.
See the OMDA income statement, the OMDA chart for price history, or the OMDA stock overview for the latest quote and news.
OMDA key metrics FAQ
What is Omada Health's P/E ratio?
Omada Health's trailing P/E ratio is 73.5 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 137.0. At the end of fiscal 2025 it was —.
What is Omada Health's return on equity?
Omada Health's return on equity (ROE) was −8.7% in fiscal 2025: net income of -$12.8 million on average shareholders' equity of $147.2 million.
What is Omada Health's ROIC?
Omada Health's return on invested capital was −72.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Omada Health's free cash flow yield?
Omada Health generated $16.9 million of free cash flow in fiscal 2025, a free cash flow yield of 1.8% on its market value at year-end ($922.0 million).
What is Omada Health's current ratio?
Omada Health's current ratio was 3.60 at the end of fiscal 2025: current assets were 3.60 times current liabilities.